A Phase 1 study to explore faster titration schemes for PRAX-944 for treatment of essential tremor (ET)
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Ulixacaltamide (Primary)
- Indications Essential tremor
- Focus Pharmacokinetics
- 03 Nov 2021 According to a Praxis Precision Medicines media release, the company has completed dosing in this trial. Topline results are expected in the fourth quarter of 2021.
- 03 Nov 2021 Status changed from planning to recruiting, according to a Praxis Precision Medicines media release.
- 15 May 2021 New trial record